



London, 30 November 2007  
Doc. Ref. EMEA/571778/2007

## COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

### Monthly Report of Application Procedures, Guidelines and Related Documents

The CVMP Monthly Report includes statistical data for the current year and the previous two ones on Scientific Advice, Initial Evaluations, Variations, Line Extensions, Renewals, MRLs Initial Evaluations and MRLs Extensions/Modifications and Arbitration and Referral procedures. In addition, the report includes a summary table of the opinions issued by the CVMP in the current year and a list of adopted Guidelines and other public documents.

#### Applications for Medicinal Products for Veterinary Use and Maximum Residue Limits (MRLs)

Scientific Advice Requests					
	95-04	2005	2006	2007	Total
Submitted	27	10	14	6	57

Initial Evaluation					
	95-04	2005	2006	2007	Total
Full <sup>1</sup>	67	11	5	13	96
Abridged/Generics	3	0	3	1	7
Withdrawals	10	1	0	0	11
Positive Opinions	51	5	13	8	77
Negative Opinions	0	0	1	0	1

Marketing Authorisations					
	95-04	2005	2006	2007	Total
Granted	45	11	10	9	75
Withdrawals	1	0	0	0	1
Not renewed	1	0	0	1	2

<sup>1</sup> Initial applications submitted and validated: 103 applications in total (full + abridged), comprising 51 immunologicals and 52 pharmaceuticals. Negative opinions: in case of appeals, the opinion will not be counted twice.

Extensions - Annex II Applications <sup>2</sup>					
	95-04	2005	2006	2007	Total
Submitted	39	8	0	9	56
Withdrawals	1	0	0	0	1
Positive Opinions	24	6	2	1	33
Negative Opinions	0	0	0	0	0

Variations – Applications submitted					
	95-04	2005	2006	2007	Total
Type IA	166	14	18	29	290
Type IB		27	13	23	
Type II	65	21	25	43	154
Transfers	5	1	1	2	9

<sup>2</sup> Extensions applications submitted and validated: 56 line extensions in total, comprising 11 immunologicals and 45 pharmaceuticals; one opinion can cover a number of extensions

Renewals					
	95-04	2005	2006	2007	Total
Submitted	18	9	2	13	42
Positive Opinions	14	10	5	10	39
Negative Opinions	0	0	0	0	0

Establishment of MRLs for new substances					
	95-04	2005	2006	2007	Total
Submitted	57	3	3	2	65
Withdrawals	5	0	0	0	5
Positive Opinions <sup>3</sup>	41	3	5	3	52
Negative Opinions <sup>4</sup>	6	0	0	0	6

Arbitrations and Community Referrals					
	95-04	2005	2006	2007	Total
Referrals Submitted	10	1	10	4	25
Opinions Reached	-	-	4	8	12

Extensions / Modifications/Extrapolations of MRLs					
	95-04	2005	2006	2007	Total
Submitted	87	5	3	1	96
Withdrawals	4	0	0	0	4
Positive Opinions <sup>3</sup>	93	8	6	3	110
Negative Opinions <sup>4</sup>	5	0	1	0	6
Extrapolations	34	6	5	0	45

<sup>3</sup> Including opinions recommending definitive MRLs for substances with previously provisional maximum residue limits

<sup>4</sup> Including one opinion concluding that final MRL could not be established for a substance with provisional maximum residue limits previously established

## CVMP Opinions in 2007 on Medicinal Products for Veterinary Use

### Positive Opinions

Product	Marketing authorisation holder	Therapeutic area	EMEA/CVMP	European Commission
<ul style="list-style-type: none"> <li>▪ Brand name</li> <li>▪ INN</li> </ul>		<ul style="list-style-type: none"> <li>▪ Target species</li> <li>▪ Summary of indication</li> </ul>	<ul style="list-style-type: none"> <li>▪ Validation</li> <li>▪ Opinion</li> <li>▪ Active time</li> <li>▪ Clock stop</li> </ul>	<ul style="list-style-type: none"> <li>▪ Opinion received</li> <li>▪ Date of decision</li> <li>▪ Notification</li> <li>▪ Official Journal</li> </ul>
<ul style="list-style-type: none"> <li>▪ Slentrol</li> <li>▪ Dirlotapide</li> </ul>	<ul style="list-style-type: none"> <li>▪ Pfizer</li> </ul>	<ul style="list-style-type: none"> <li>▪ Dogs</li> <li>▪ Obesity ATC code</li> </ul>	<ul style="list-style-type: none"> <li>▪ 21/02/2006</li> <li>▪ 14/02/2007</li> <li>▪ 209</li> <li>▪ 148</li> </ul>	<ul style="list-style-type: none"> <li>▪ 19/02/2007</li> <li>▪ 13/04/2007</li> </ul>
<ul style="list-style-type: none"> <li>▪ Suprelorin</li> <li>▪ Deslorelin</li> </ul>	<ul style="list-style-type: none"> <li>▪ Cyton Biosciences Ltd</li> </ul>	<ul style="list-style-type: none"> <li>▪ Dogs</li> <li>▪ temporary infertility in male dogs</li> </ul>	<ul style="list-style-type: none"> <li>▪ 20/09/2005</li> <li>▪ 15/05/2007</li> <li>▪ 211</li> <li>▪ 301</li> </ul>	<ul style="list-style-type: none"> <li>▪ 12/06/2007</li> <li>▪ 10/07/2007</li> </ul>
<ul style="list-style-type: none"> <li>▪ Nobilis Influenza H7N1</li> <li>▪ Vaccine</li> </ul>	<ul style="list-style-type: none"> <li>▪ Intervet International bv</li> </ul>	<ul style="list-style-type: none"> <li>▪ Chickens</li> <li>▪ Vaccine against avian influenza</li> </ul>	<ul style="list-style-type: none"> <li>▪ 18/10/2006</li> <li>▪ 14/03/2007</li> <li>▪ 120</li> <li>▪ 28</li> </ul>	<ul style="list-style-type: none"> <li>▪ 15/03/2007</li> <li>▪ 14/05/2007</li> </ul>
<ul style="list-style-type: none"> <li>▪ Prilactone</li> <li>▪ Spironolactone</li> </ul>	<ul style="list-style-type: none"> <li>▪ Ceva Sante Animale</li> </ul>	<ul style="list-style-type: none"> <li>▪ a) Dogs</li> <li>▪ b) Heart failure</li> </ul>	<ul style="list-style-type: none"> <li>▪ 07/06/2005</li> <li>▪ 17/04/2007</li> <li>▪ 210</li> <li>▪ 469</li> </ul>	<ul style="list-style-type: none"> <li>▪ 22/05/2007</li> <li>▪ 20/06/2007</li> </ul>

<b>Product</b> ▪ Brand name ▪ INN	<b>Marketing authorisation holder</b>	<b>Therapeutic area</b> ▪ Target species ▪ Summary of indication	<b>EMEA/CVMP</b> ▪ Validation ▪ Opinion ▪ Active time ▪ Clock stop	<b>European Commission</b> ▪ Opinion received ▪ Date of decision ▪ Notification ▪ Official Journal
▪ Circovac ▪ Inactivated vaccine	▪ Merial	▪ Pigs ▪ b) passive immunity against porcine circovirus type 2.	▪ 21/12/2005 ▪ 17/04/2007 ▪ 210 ▪ 274	▪ 15/05/2007 ▪ 21/06/2007
▪ Nobilis Influenza H5N6 ▪ Vaccine	▪ Intervet International BV	▪ Birds ▪ Prevention of avian influenza	▪ 13/02/2007 ▪ 11/07/2007 ▪ 90 ▪ 28	▪
▪ Meloxivet ▪ Meloxicam	▪ Janssen Pharmaceutica N.V.	▪ Dogs ▪ Musculo-skeletal disorders	▪ 19/12/2006 ▪ 12/09/2007 ▪ 210 ▪ 57	▪ 14/11/2007
▪ Rheumocam ▪ Meloxicam	▪ Chanelle Pharmaceuticals	▪ Dogs ▪ Musculo-skeletal disorders	▪ 18/08/2007 ▪ 07/11/2007 ▪ 208 ▪ 231	▪

#### Negative Opinions

<b>Product</b> ▪ Brand name ▪ INN	<b>Marketing authorisation holder</b>	<b>Therapeutic area</b> ▪ Target species ▪ Summary of indication	<b>EMEA/CVMP</b> ▪ Validation ▪ Opinion ▪ Active time ▪ Clock stop	<b>European Commission</b> ▪ Opinion received ▪ Date of decision ▪ Notification ▪ Official Journal
▪	▪	▪	▪	▪

#### Withdrawals prior to opinion

<b>Product</b> ▪ Brand name ▪ INN	<b>Marketing authorisation holder</b>	<b>Therapeutic area</b> ▪ Target species ▪ Summary of indication	<b>EMEA/CVMP</b> ▪ Validation ▪ Opinion ▪ Active time ▪ Clock stop	<b>European Commission</b> ▪ Opinion received ▪ Date of decision ▪ Notification ▪ Official Journal
▪		▪	▪	▪

### CVMP Opinions in 2007 on establishment of MRLs for new substances

#### Positive Opinions

<b>Substance INN</b>	<b>Therapeutic area</b> ▪ Target species	<b>EMEA/CVMP</b> ▪ Validation ▪ Opinion ▪ Active time ▪ Clock stop	<b>European Commission</b> ▪ Opinion received ▪ Date of regulation ▪ Official Journal
▪ Avilamycin	▪ Pigs, poultry and rabbits	▪ 13/01/2005 ▪ 10/10/2007 ▪ 120 ▪ 670	▪ 24/10/2007

<b>Substance INN</b>	<b>Therapeutic area</b> ▪ Target species	<b>EMEA/CVMP</b> ▪ Validation ▪ Opinion ▪ Active time ▪ Clock stop	<b>European Commission</b> ▪ Opinion received ▪ Date of regulation ▪ Official Journal
▪ Monensin	▪ Dairy Cattle	▪ 17/02/2005 ▪ 15/05/2007 ▪ 119 ▪ 698	▪ 12/06/2007
▪ Gamithromycin	▪ Bovine	▪ 10/08/2006 ▪ 10/10/2007 ▪ 117 ▪ 215	▪ 24/10/2007

### Arbitrations and Community Referrals in 2007

<b>Type of referral</b>	<b>Date of CVMP opinion</b>	<b>Product name</b> ▪ INN
Referral for arbitration – Art. 33(4) Directive 2001/82/EC	17/1/2007	▪ Equimectin 12mg/g ▪ Ivermectin
Referral for arbitration – Art.40 Directive 2001/82/EC	17/01/2007	▪ Suvaxyn Parvo E ▪ Inactivated porcine parvovirus, strain S-80, Inactivated Erysipelothrix rhusiopathiae, strain B-7 (serotype 2)
Referral for arbitration – Art.40 Directive 2001/82/EC	17/01/2007	▪ Suvaxyn Ery ▪ Inactivated Erysipelothrix rhusiopathiae, strain B-7 (serotype 2)
Referral for arbitration – Art. 33(4) Directive 2001/82/EC	14/02/2007	▪ Doxyprex 100 mr/g ▪ Doxycycline base as hyclate
Referral for arbitration – Art. 33(4) Directive 2001/82/EC	17/04/2007	▪ Bovilis BVD ▪ Inactivated BVDV strain C-86
Referral for arbitration – Art. 33(4) Directive 2001/82/EC	18/04/2007	▪ Enurace 50 ▪ Ephedrine
Referral for arbitration - Art. 33(4) Directive 2001/82/EC	11/072007 (clock start)	▪ Ecomectin 18.7 mg/g ▪ Ivermectin
Referral for arbitration – Art. 35 of Directive 2001/82/EC	07/11/2007	▪ Sulfatrim Oral Doser (Tribrissen and generics) ▪ Trimethoprim - Sulfadiazine
Referral under – Art. 35 of Directive 2001/82/EC	11/10/2007 (clock start)	▪ Toltrazuril (former (Baycox 2.5%)) ▪ Toltrazuril
Referral for arbitration – Art. 34(1) Directive 2001/82/EC	10/10/2007	▪ Methoxasol-T ▪ Trimethoprim and sulfamethoxazole

## Guidelines and Working Documents in 2007

### CVMP Efficacy

Reference number	Document title	Status
EMEA/CVMP/EWP/170208/2005	Guideline on the summary of product characteristics for anthelmintics	Adopted July 2007
EMEA/CVMP/EWP/362275/2007-CONSULTATION	Concept paper for the revision of the guideline on “Veterinary medicinal products controlling <i>Varroa destructor</i> and <i>Acarapis woodi</i> parasitosis in bees”	Adopted for consultation September 2007. (End of consultation: March 2008)
EMEA/CVMP/EWP/85954/2007-CONSULTATION	Concept paper for the revision of the “Guideline on Efficacy of veterinary medicinal products for use in farmed aquatic species”	Adopted for consultation October 2007 (end of consultation: January 2008)
EMEA/CVMP/EWP/005/2000-Rev.2	Guideline for the Testing and Evaluation of the Efficacy of Antiparasitic Substances for the Treatment and Prevention of Tick and Flea Infestation in Dogs and Cats	Adopted November 2007 (Implementation 1 June 2008)

### CVMP Environmental Risk Assessment (ERA)

Reference number	Document title	Status
EMEA/CVMP/ERA/418282/2005	Guideline on Environmental Impact Assessment for VMPs in support of the VICH guidelines GL6 and GL38	Adopted April 2007

### CVMP Immunologicals

Reference number	Document title	Status
EMEA/CVMP/IWP/23332/2006	Guideline on user safety for immunological veterinary medicinal products”	Adopted April 2007
EMEA/CVMP/IWP/222624/2006	Guideline on data requirements for an authorisation under exceptional circumstances for vaccines in birds against avian influenza”	Adopted April 2007
EMEA/CVMP/IWP/205351/2006	Guideline on the procedure to be followed when a batch of a vaccine finished product is suspected to be contaminated with bovine viral diarrhoea (BVD) virus”	Adopted April 2007

EMEA/CVMP/IWP/105008/2007	Reflection paper on minimum data requirements for an authorisation under exceptional circumstances for vaccines for emergency use against Bluetongue”	Adopted April 2007
EMEA/CVMP/IWP/501304/2006	Concept paper on the need for requiring data to demonstrate the influence of maternally derived antibody on the vaccination of very young animals”	Adopted April 2007
EMEA/CVMP/IWP/90459/2007	Concept paper on requirements for multi-strain dossiers”	Adopted April 2007
EMEA/CVMP/IWP/123243/2007	Guideline on data requirements for immunological veterinary medicinal products intended for minor use or minor species/limited markets	Adopted July 2007

### CVMP Pharmacovigilance

Reference number	Document title	Status
EMEA/CVMP/PhVWP/73213/2007	EMEA Public Bulletin 2006 on Veterinary Pharmacovigilance on activities regarding pharmacovigilance for veterinary medicinal products during the past year	Adopted February 2007
EMEA/INS/PhV/47075/2007	Guideline on monitoring of compliance with pharmacovigilance regulatory obligations and pharmacovigilance inspections	Adopted February 2007. Published on the European Commission website on 4 April 2007
SOP/V/4023	Procedure for management of Periodic Safety Update Reports (PSURs) for centrally authorised products	Adopted March 2007
EMEA/CVMP/413/99-Rev.4	VEDDRA list of clinical terms for adverse reactions in animals	Adopted June 2007
EMEA/CVMP/891/04-Rev.2	VEDDRA list of clinical terms for adverse reactions in humans	Adopted June 2007
EMEA/CVMP/553/03-Rev.2	List of species and breeds	Adopted June 2007
Published by the European Commission’s EudraLex	Pharmacovigilance for Veterinary Medicinal Products – Procedures for Marketing Authorisation Holders	Adopted June 2007
EMEA/CVMP/PhVWP/4550/2006-CONSULTATION	Guideline on Management and Assessment of Periodic Safety Update Reports (PSURs) of Veterinary Medicinal Products	Adopted for consultation October 2007 (end of consultation: April 2008)

## Joint CHMP/CVMP Quality

Reference number	Document title	Status
EMA/ CVMP/ VICH/ 899/ 99- Rev. 1	Stability testing of new veterinary drug substances and medicinal products	Adopted February 2007
EMA/ CVMP/ VICH/ 837/ 99- Rev. 1	Impurities in new veterinary drug substances	Adopted February 2007
EMA/ CVMP/ VICH/ 838/ 99- Rev. 1	Impurities in new veterinary medicinal products	Adopted February 2007
EMA/ CVMP/ QWP/ 103377/ 2007	Concept Paper on the revision of the CVMP guideline on stability testing of existing active substances and related finished products	Adopted April 2007
EMA/ HMPC/ CHMP/ CVMP/ 287 539/ 2005	Guideline on the Declaration of Herbal Substances in the SPC	Adopted July 2007
EMA/ CHMP/ CVMP/ QWP/ 22193 0/ 2007-CONSULTATION	Guideline on the Quality of Combination Herbal Medicinal Products / Traditional Herbal Medicinal Products	Adopted for consultation July 2007 (end of consultation October 2007)
EMA/ CVMP/ QWP/ 846/ 99-Rev. 1	Revised Guideline on Stability Testing: Stability testing of existing active substances and related finished products	Adopted for consultation October 2007 (end of consultation: April 2008)

## CVMP Safety

Reference number	Document title	Status
EMA/ CVMP/ 95682/ 2007-CONSULTATION	Reflection paper on assessment of bioavailability of bound residues in food commodities of animal origin in the context of Council Regulation (EEC) No 2377/90	Adopted for consultation May 2007 (end of consultation November 2007)
EMA/ CVMP/ VICH/ 1052/ 2004	“VICH GL41 Target animal safety: examination of live veterinary vaccines in target animals for absence of reversion to virulence”	Adopted September 2007 (Implementation: July 2008)
EMA/ CVMP/ VICH/ 359665/ 2005-CONSULTATION	“VICH GL44 Guideline Target Animal Safety for veterinary live and inactivated vaccines”	Adopted for consultation September 2007 (end of consultation: March 2008)

## CVMP Scientific Advisory Group on Antimicrobials

Reference number	Document title	Status
EMA/VA/CP/383441/2005	Revised guideline on the SPC for antimicrobial products	Adopted November 2007 (Implementation 1 May 2008)
EMA/VA/CP/184651/2005	Public statement on the use of (fluoro)quinolones in food-producing animals in the European Union: development of resistance and impact on human and animal health	Adopted February 2007

## CVMP General

Reference number	Document title	Status
EMA/VA/CP/422/04-Rev.1	Revised CVMP rules of procedure	Adopted in February 2007
EMA/VA/CP/4789/2007	Procedure for the nomination and appointment of co-opted members of the Committee	Adopted March 2007
SOP/INSP/2019	Coordination of pre-approval GxP Inspections	Adopted April 2007
EMA/VA/CP/328/98-Rev.3-CONSULTATION	The acceptability of names for veterinary medicinal products processed through the centralised procedure	Adopted for consultation June 2007 (end of consultation: September 2007)
EMA/VA/CP/425558/2006	Reflection paper on Withdrawals of Marketing Authorisation Applications for Veterinary Medicinal Products	Adopted July 2007
EMA/VA/CP/459912/2006	Reflection paper on the publication of the CVMP's Negative Opinion and Refusal to Recommend the granting of a Marketing Authorisation for Veterinary Medicinal Products	Adopted July 2007
EMA/VA/CP/248499/2007-CONSULTATION	Guideline on the evaluation of the benefit-risk balance of veterinary medicinal products	Adopted for consultation September 2007. (end of consultation March 2008)
EMA/VA/CP/2128/2007	Guideline on procedures for re-examination of CVMP opinions	Adopted September 2007
EMA/VA/CP/358850/2007-CONSULTATION	Concept paper on the classification of veterinary medicinal products authorised by the Community	Adopted for consultation September 2007. (end of consultation: November 2007)
EMA/VA/CP/120559/2006	Questions and answers document regarding application of the so-called 'sunset clause' to centrally authorised veterinary medicinal products	Adopted October 2007